Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: herold t. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Reis H, Metzenmacher M, Goetz M, Savvidou N, Darwiche K, Aigner C, Herold T, Eberhardt WE, Skiba C, Hense J, Virchow I, Westerwick D, Bogner S, Ting S, Kasper S, Stuschke M, Nensa F, Herrmann K, Hager T, Schmid KW, Schuler M, Wiesweg M. Reis H, et al. Among authors: herold t. Clin Lung Cancer. 2018 Jul;19(4):e441-e463. doi: 10.1016/j.cllc.2018.03.010. Epub 2018 Mar 17. Clin Lung Cancer. 2018. PMID: 29631966
Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
Wiesweg M, Kasper S, Worm K, Herold T, Reis H, Sara L, Metzenmacher M, Abendroth A, Darwiche K, Aigner C, Wedemeyer HH, Helfritz FA, Stuschke M, Schumacher B, Markus P, Paul A, Rahmann S, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: herold t. Oncogene. 2019 Apr;38(16):2953-2966. doi: 10.1038/s41388-018-0634-0. Epub 2018 Dec 19. Oncogene. 2019. PMID: 30568222
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Scheffler M, Wiesweg M, Michels S, Nogová L, Kron A, Herold T, Scheel AH, Metzenmacher M, Eberhardt WE, Reis H, Fassunke J, Darwiche K, Aigner C, Schaufler D, Riedel R, Fischer R, Koleczko S, Schildhaus HU, Merkelbach-Bruse S, Schmid KW, Büttner R, Wolf J, Schuler M. Scheffler M, et al. Among authors: herold t. Lung Cancer. 2022 Jun;168:10-20. doi: 10.1016/j.lungcan.2022.04.006. Epub 2022 Apr 16. Lung Cancer. 2022. PMID: 35461051
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H, Herold T, Ting S, Worm K, Huber U, Christoph DC, Eberhardt WE, Kostbade K, Kasper S, Stamatis G, Welter S, Darwiche K, Karpf-Wissel R, Theegarten D, Schmid KW, Schuler M, Wiesweg M. Reis H, et al. Among authors: herold t. Lung Cancer. 2015 Apr;88(1):34-41. doi: 10.1016/j.lungcan.2015.02.002. Epub 2015 Feb 7. Lung Cancer. 2015. PMID: 25708529
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: herold t. J Thorac Oncol. 2017 Jan;12(1):54-64. doi: 10.1016/j.jtho.2016.08.137. Epub 2016 Aug 27. J Thorac Oncol. 2017. PMID: 27575422 Free article.
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Köhler J, Herold T, Schmid KW, Freitag L, Kasper S, Schuler M. Breitenbuecher F, et al. Among authors: herold t. PLoS One. 2014 Jan 21;9(1):e85350. doi: 10.1371/journal.pone.0085350. eCollection 2014. PLoS One. 2014. PMID: 24465542 Free PMC article. Clinical Trial.
293 results